Mcrc - OmicsDI

Show results for

Unknown (1513)
Clinical (490)
Genomics (124)
Transcriptomics (60)
Proteomics (18)
Other (4)
Methylation profiling (3)

Organisms

Homo sapiens (89)
Alphavirus (15)
Anemia (15)
Archaea (15)
Bacteria (15)
Betaherpesvirinae (15)
Borrelia (15)
Chlorella vulgaris (15)
Clostridium perfringens (15)
Dengue virus (15)
Enterovirus A71 (15)
Eukaryota (15)
Hepatitis B virus (15)
Human alphaherpesvirus 1 (15)
Human betaherpesvirus 5 (15)
Influenza A virus (15)
Influenza C virus (15)
Japanese encephalitis virus group (15)
Kamptonema sp. (15)
Listeria monocytogenes (15)
Mammarenavirus (15)
Miscanthus x giganteus (15)
Mycobacterium tuberculosis (15)
Orthoflavivirus (15)
Panicum virgatum (15)
Pseudomonas aeruginosa (15)
Rattus (15)
Severe acute respiratory syndrome coronavirus 2 (15)
Staphylococcus aureus (15)
Mus musculus (14)

Organisms

Homo sapiens (60)
Mus musculus (15)

Repository

ENA (91)
geo (67)
EGA (22)
pride (15)
biostudies-arrayexpress (11)
iProX (3)

Tissue

Cell culture (3)
Colon (3)
Epithelial cell (3)
Liver (2)
Blood (1)
Blood plasma (1)
Bone marrow (1)
Breast (1)
Colon epithelial cell (1)
Colorectal adenocarcinoma cell line (1)
Malignant cell (1)
Natural killer cell (1)
Permanent cell line cell (1)

Disease

Colorectal Neoplasms (361)
Metastatic colorectal cancer (18)
Carcinoma (9)
Neoplasms (9)
Colorectal cancer metastatic (8)
Colorectal cancer (8)
Colorectal cancer (7)
Neoplasm Metastasis (6)
Metastatic Colorectal Cancer (4)
Adenocarcinoma (4)
Advanced colorectal cancer (3)
Metastatic colorectal cancer (3)
Malignant neoplasm of rectum (2)
Colorectal neoplasms malignant (2)
Malignant neoplasm of colon, unspecified (2)
Rectal Neoplasms (2)
Microsatellite stable (MSS) metastatic colorectal cancer (mCRC) (1)
Patients with mCRC with an indication for lonsurf treatment. (1)
Colorectal cancer liver metastases (CRLM) (1)
Gastrointestinal neoplasms malignant and unspecified (1)
Inoperable, untreated, wild type RAS (wt KRAS/wtNRAS), metastatic colorectal cancer (mCRC) (1)
Gastrointestinal cancer metastatic (1)
Advanced colorectal tumors (1)
GIST and mCRC patients (1)
METASTATIC COLORECTAL CANCER (1)
Previously untreated, wild-type RAS, potentially resectable colorectal cancer liver metastases (1)
CRC (1)
 Patients with histologically confirmed diagnosis of metastatic Colorectal Cancer (CRC) including potentially resectable liver metastases, untreated yet with chemotherapy for metastatic disease (1)
MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND A HIGH IMMUNE INFILTRATE (1)
Resectable advanced colorectal cancer (1)

Technology Type

Mass Spectrometry (15)
Shotgun proteomics (9)
Bottom-up proteomics (3)
Data-dependent acquisition (2)
Data-independent acquisition (2)
Affinity purification coupled with mass spectrometry proteomics (1)

Publication Date

2025 (22)
2023 (15)
2013 (10)
2022 (10)
2024 (9)
2026 (8)
2012 (6)
2019 (4)
2021 (3)
2018 (3)
2014 (2)
2020 (2)
2016 (1)
2017 (1)

First Public Date

2025 (23)
2023 (14)
2022 (14)
2024 (13)
2026 (8)
2014 (7)
2021 (4)
2020 (3)
2013 (2)
2018 (1)
2017 (1)
2015 (1)

Study status

Completed (193)
Recruiting (96)
Not provided (54)
Active, not recruiting (47)
Terminated (35)
Not yet recruiting (26)
Ongoing (19)
Withdrawn (16)
Suspended (3)
No longer available (1)

Study type

Interventional (401)
Observational (77)
Observational patient registry (10)
Transcription profiling by array (8)
Human - One-color microarray (1)
Transcription profiling by RT-PCR (1)
Comparative genomic hybridization by array (1)
Expanded access (1)
Other (1)

Release Date

2022 (216)
2023 (185)
2021 (180)
2020 (144)
2019 (123)
2024 (120)
2025 (118)
2018 (112)
2017 (75)
2016 (68)
2015 (65)
2014 (40)
2013 (22)
2012 (17)
2026 (16)
2011 (10)
2010 (10)
2008 (2)
2009 (1)

Lab affiliation

Centre for Applied Bioanthropology, Institute for Anthropological Research, Zagreb, Croatia (2)
Debora Bonenfant, Novartis Institutes for BioMedical Research, Basel, Switzerland (2)
Amsterdam UMC, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, OncoProteomics Laboratory, Amsterdam, Netherlands (1)
Cell matrix biology and regenerative medicine, School of biological sciences, University of manchester (1)
Chair of Proteomics and Bioanalytics Technical University of Munich Germany (1)
German Cancer Research Center (DKFZ),Division Systems Biology of Signal Transduction, INF 280, 69120 Heidelberg (1)
Head of the Laboratory of Rare Human Circulating Cells – University Medical Center of Montpellier – France (1)
Leibniz-Institut für Analytische Wissenschaften – ISAS – e.V., Otto-Hahn-Str. 6b, 44227 Dortmund, Germany (1)
Maimónides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain Cancer Network Biomedical Research Centre (CIBERONC), Madrid, Spain Medical Oncology Department, Reina Sofía University Hospital, Córdoba, Spain (1)
Molecular Cancer Research, Center for Molecular Medicine, University Medical Center Utrecht, CX Utrecht, the Netherlands (1)
Peking University Cancer Hospital & Institute. (1)
University of Tübingen, Interfaculty Institute for Cell Biology, Department of Immunology, Auf der Morgenstelle 15, 72076 Tuebingen, Germany (1)
University of Vienna, Faculty of Chemistry, Department of Analytical Chemistry (1)

Location

United States (102)
China (99)
Italy (97)
Spain (92)
France (80)
Germany (74)
Belgium (56)
United Kingdom (47)
Japan (39)
Netherlands (34)
Canada (32)
Australia (30)
Austria (30)
South Korea (28)
Taiwan (24)
Poland (24)
Russia (20)
Denmark (17)
India (16)
Czechia (16)
Argentina (15)
Sweden (14)
Ukraine (13)
Greece (13)
Israel (13)
Romania (12)
Hungary (12)
Brazil (12)
Turkey (11)
Portugal (11)

Keyword

Irinotecan (94)
Bevacizumab (94)
Cetuximab (70)
Leucovorin (65)
Oxaliplatin (65)
Fluorouracil (63)
MCRC (45)
Capecitabine (41)
Levoleucovorin (35)
Panitumumab (33)
Trifluridine (20)
FOLFIRI (17)
Regorafenib (16)
Metastatic (16)
Nivolumab (15)
Aflibercept (13)
Metastatic colorectal cancer (13)
Colorectal (12)
Folic Acid (12)
Pembrolizumab (12)
Erbitux (11)
CRC (10)
Tislelizumab (8)
Metastatic Colorectal Cancer (8)
Ipilimumab (8)
KRAS (8)
Immunotherapy (8)
Vectibix (7)
Oxaliplatino (7)
Atezolizumab (7)

Previous page
1 / 222
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 222
Next page

Sort by:

Relevance

Page size

scRNA mCRC PDO

scRNA of five mCRC organoids in basal conditions

EGAS00001006214 | EGA

Whole genome copy number profiles of FFPE samples from patients with metasatic colorectal cancer (mCRC)

PRJNA434557 | ENA

Bulk RNAseq of mCRC organoids

Transcriptomic profiles of 6 mCRC organoids

EGAS00001006727 | EGA

The EP4 antagonist vorbipiprant and an anti-PD-1 in MSS mCRC

PRJNA1183748 | ENA

Whole genome copy number profiles of FFPE samples from patients with metasatic colorectal cancer (mCRC)

Metastatic colorectal cancer (mCRC) is associated with multiple somatic copy number alterations (SCNAs). We analyzed SCNAs to estimate overall survival (OS) and progression free suvival (PFS) for mCRC patients treated with bevacizumab in combination with oxaliplatin or irinotecan.

ORGANISM(S): Homo sapiens

2018-11-21 | GSE110785 | GEO

Gene signature predictive of response to chemotherapy in mCRC [array]

The objective is to generate a robust and validated predictor profile for chemotherapy response in patients with mCRC using microarray gene expression profiles of primary colorectal cancer tissue.

ORGANISM(S): Homo sapiens

2013-12-01 | GSE52735 | GEO

Gene signature predictive of response to chemotherapy in mCRC [RT-PCR]

The objective is to generate a robust and validated predictor profile for chemotherapy response in patients with mCRC using microarray gene expression profiles of primary colorectal cancer tissue.

ORGANISM(S): Homo sapiens

2013-11-20 | GSE52513 | GEO

The EP4 antagonist vorbipiprant and an anti-PD-1 in MSS mCRC

The aim of the study was to determine whether vorbipiprant, a prostaglandin EP4 receptor antagonist, can convert immune-resistant mCRC into a tumor responsive to anti-PD-1 inhibition

ORGANISM(S): Homo sapiens

2024-11-12 | GSE281374 | GEO

Gene signature predictive of response to chemotherapy in mCRC [array]

The objective is to generate a robust and validated predictor profile for chemotherapy response in patients with mCRC using microarray gene expression profiles of primary colorectal cancer tissue. To define a gene signature of response to chemotherapy in metastatic colorectal cancer, samples were ob...

ORGANISM(S): Homo sapiens

2013-12-01 | E-GEOD-52735 | biostudies-arrayexpress

Monitoring of RAS/EGFR mutations in circulating tumor DNA to guide anti-EGFR therapy in mCRC patients: The CHRONOS trial

PRJEB49484 | ENA

Previous page
1 / 222
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 222
Next page

Sort by:

Relevance

Page size

2212 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Publication Date

First Public Date

Study status

Study type

Release Date

Lab affiliation

Location

Tags

Keyword

OmicsDI is part of the ELIXIR infrastructure

Tweets